Loading cancer entity…
Loading cancer entity…
Clinical trials
121 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (27)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05321940 | Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias | withdrawn | Phase 1 | 0 | Juan C. Ramos, MDOTHER | 0 | Dec 4, 2023 | clinicaltrials |
| NCT05513612 | Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies | withdrawn | Phase 1 | 0 | Shanghai Pudong HospitalOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT04639843 |
| Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma |
| withdrawn |
| Phase 1 |
| 0 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Nov 4, 2022 |
| clinicaltrials |
Data updated 23 days agoSource updated Dec 4, 2023source: clinicaltrials